Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas

Chengfeng Bi, Xuan Zhang, Ting Lu, Xiaoyan Zhang, Xianhuo Wang, Bin Meng, Huilai Zhang, Ping Wang, Julie Marie Vose, Wing C. Chan, Timothy W. McKeithan, Kai Fu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Mechanistic target of rapamycin (mTOR) complex 1 is a central integrator of nutrient and growth factor inputs that controls cell growth in eukaryotes. The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatment, particularly in inducing apoptosis. However, the mechanism underlying the cytotoxic effect of TORKi remains elusive. Herein, we demonstrate that TORKi-induced apoptosis is predominantly dependent on the loss of mTOR complex 1-mediated 4EBP activation. Knocking out RICTOR, a key component of mTOR complex 2, or inhibiting p70S6K has little effect on TORKi-induced apoptosis. Conversely, increasing the eIF4E:4EBP ratio by either overexpressing eIF4E or knocking out 4EBP1/2 protects lymphoma cells from TORKi-induced cytotoxicity. Furthermore, downregulation of MCL1 expression plays an important role in TORKi-induced apoptosis, whereas BCL-2 overexpression confers resistance to TORKi treatment. We further show that the therapeutic effect of TORKi in aggressive B-cell lymphomas can be predicted by BH3 profiling, and improved by combining it with pro-apoptotic drugs, especially BCL-2 inhibitors, both in vitro and in vivo. Taken together, the study herein provides mechanistic insight into TORKi cytotoxicity and identified a potential way to optimize its efficacy in the clinical treatment of aggressive B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)755-764
Number of pages10
JournalHaematologica
Volume102
Issue number4
DOIs
StatePublished - Mar 31 2017

Fingerprint

B-Cell Lymphoma
Sirolimus
Phosphotransferases
Phosphorylation
Apoptosis
70-kDa Ribosomal Protein S6 Kinases
Prodrugs
Therapeutic Uses
Eukaryota
Lymphoma
Catalytic Domain
Intercellular Signaling Peptides and Proteins
Down-Regulation
Food
Growth
Neoplasms
mechanistic target of rapamycin complex 1

ASJC Scopus subject areas

  • Hematology

Cite this

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. / Bi, Chengfeng; Zhang, Xuan; Lu, Ting; Zhang, Xiaoyan; Wang, Xianhuo; Meng, Bin; Zhang, Huilai; Wang, Ping; Vose, Julie Marie; Chan, Wing C.; McKeithan, Timothy W.; Fu, Kai.

In: Haematologica, Vol. 102, No. 4, 31.03.2017, p. 755-764.

Research output: Contribution to journalArticle

Bi, Chengfeng ; Zhang, Xuan ; Lu, Ting ; Zhang, Xiaoyan ; Wang, Xianhuo ; Meng, Bin ; Zhang, Huilai ; Wang, Ping ; Vose, Julie Marie ; Chan, Wing C. ; McKeithan, Timothy W. ; Fu, Kai. / Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. In: Haematologica. 2017 ; Vol. 102, No. 4. pp. 755-764.
@article{02a6d38742874e83b494b45e4cc70153,
title = "Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas",
abstract = "Mechanistic target of rapamycin (mTOR) complex 1 is a central integrator of nutrient and growth factor inputs that controls cell growth in eukaryotes. The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatment, particularly in inducing apoptosis. However, the mechanism underlying the cytotoxic effect of TORKi remains elusive. Herein, we demonstrate that TORKi-induced apoptosis is predominantly dependent on the loss of mTOR complex 1-mediated 4EBP activation. Knocking out RICTOR, a key component of mTOR complex 2, or inhibiting p70S6K has little effect on TORKi-induced apoptosis. Conversely, increasing the eIF4E:4EBP ratio by either overexpressing eIF4E or knocking out 4EBP1/2 protects lymphoma cells from TORKi-induced cytotoxicity. Furthermore, downregulation of MCL1 expression plays an important role in TORKi-induced apoptosis, whereas BCL-2 overexpression confers resistance to TORKi treatment. We further show that the therapeutic effect of TORKi in aggressive B-cell lymphomas can be predicted by BH3 profiling, and improved by combining it with pro-apoptotic drugs, especially BCL-2 inhibitors, both in vitro and in vivo. Taken together, the study herein provides mechanistic insight into TORKi cytotoxicity and identified a potential way to optimize its efficacy in the clinical treatment of aggressive B-cell lymphoma.",
author = "Chengfeng Bi and Xuan Zhang and Ting Lu and Xiaoyan Zhang and Xianhuo Wang and Bin Meng and Huilai Zhang and Ping Wang and Vose, {Julie Marie} and Chan, {Wing C.} and McKeithan, {Timothy W.} and Kai Fu",
year = "2017",
month = "3",
day = "31",
doi = "10.3324/haematol.2016.159160",
language = "English (US)",
volume = "102",
pages = "755--764",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "4",

}

TY - JOUR

T1 - Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas

AU - Bi, Chengfeng

AU - Zhang, Xuan

AU - Lu, Ting

AU - Zhang, Xiaoyan

AU - Wang, Xianhuo

AU - Meng, Bin

AU - Zhang, Huilai

AU - Wang, Ping

AU - Vose, Julie Marie

AU - Chan, Wing C.

AU - McKeithan, Timothy W.

AU - Fu, Kai

PY - 2017/3/31

Y1 - 2017/3/31

N2 - Mechanistic target of rapamycin (mTOR) complex 1 is a central integrator of nutrient and growth factor inputs that controls cell growth in eukaryotes. The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatment, particularly in inducing apoptosis. However, the mechanism underlying the cytotoxic effect of TORKi remains elusive. Herein, we demonstrate that TORKi-induced apoptosis is predominantly dependent on the loss of mTOR complex 1-mediated 4EBP activation. Knocking out RICTOR, a key component of mTOR complex 2, or inhibiting p70S6K has little effect on TORKi-induced apoptosis. Conversely, increasing the eIF4E:4EBP ratio by either overexpressing eIF4E or knocking out 4EBP1/2 protects lymphoma cells from TORKi-induced cytotoxicity. Furthermore, downregulation of MCL1 expression plays an important role in TORKi-induced apoptosis, whereas BCL-2 overexpression confers resistance to TORKi treatment. We further show that the therapeutic effect of TORKi in aggressive B-cell lymphomas can be predicted by BH3 profiling, and improved by combining it with pro-apoptotic drugs, especially BCL-2 inhibitors, both in vitro and in vivo. Taken together, the study herein provides mechanistic insight into TORKi cytotoxicity and identified a potential way to optimize its efficacy in the clinical treatment of aggressive B-cell lymphoma.

AB - Mechanistic target of rapamycin (mTOR) complex 1 is a central integrator of nutrient and growth factor inputs that controls cell growth in eukaryotes. The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatment, particularly in inducing apoptosis. However, the mechanism underlying the cytotoxic effect of TORKi remains elusive. Herein, we demonstrate that TORKi-induced apoptosis is predominantly dependent on the loss of mTOR complex 1-mediated 4EBP activation. Knocking out RICTOR, a key component of mTOR complex 2, or inhibiting p70S6K has little effect on TORKi-induced apoptosis. Conversely, increasing the eIF4E:4EBP ratio by either overexpressing eIF4E or knocking out 4EBP1/2 protects lymphoma cells from TORKi-induced cytotoxicity. Furthermore, downregulation of MCL1 expression plays an important role in TORKi-induced apoptosis, whereas BCL-2 overexpression confers resistance to TORKi treatment. We further show that the therapeutic effect of TORKi in aggressive B-cell lymphomas can be predicted by BH3 profiling, and improved by combining it with pro-apoptotic drugs, especially BCL-2 inhibitors, both in vitro and in vivo. Taken together, the study herein provides mechanistic insight into TORKi cytotoxicity and identified a potential way to optimize its efficacy in the clinical treatment of aggressive B-cell lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=85016964927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016964927&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.159160

DO - 10.3324/haematol.2016.159160

M3 - Article

C2 - 28104700

AN - SCOPUS:85016964927

VL - 102

SP - 755

EP - 764

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 4

ER -